Testing a new drug to lower antibodies for kidney transplant
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests a drug called BiTE to reduce high antibody levels (cPRA ≥90%) in people waiting for a kidney transplant. If it works, it might help you become eligible for a transplant sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old.
- You have end-stage kidney disease and have been waiting for a kidney transplant for 5 years or more.
- Your antibody level (cPRA) is 90% or higher.
- You have already tried standard antibody-lowering treatments (like IVIG or plasmapheresis) but they didn't work well enough.
- Your heart, lungs, and liver are working well enough for the treatment.
- You haven't had a bone marrow, stem cell, or other organ transplant before.
- You are not pregnant, breastfeeding, or planning pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
This study tests whether a special immune therapy called a BiTE (bispecific T-cell engager) can safely help your body accept a kidney from a donor with a different blood type. It may reduce the need for strong anti-rejection medicines and improve transplant success.
This study tests whether a medication called belimumab can help people who are highly sensitized (their immune system has many antibodies against donor organs) become eligible for kidney transplant by improving how doctors understand their antibody patterns. The goal is to help these patients access transplants more easily.
This study looks at how memory B cells (a type of immune cell) relate to antibodies against HLA in people waiting for a kidney transplant. It aims to better understand immune responses, which could help improve transplant matching and outcomes.
This trial tests a medication called belatacept to see if it can prevent or treat early antibody-mediated rejection in kidney transplant recipients who have developed new donor-specific antibodies but still have stable kidney function.
Hear when a new Kidney Transplantation Recipients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.